Shear-induced pathway of platelet function in cardiac surgery.

abstract：:Plasma levels of total homocysteine (tHcy), a possible risk factor for vascular disease, are generally lower in women than in men and lower in premenopausal women than in postmenopausal women. This article reviews studies that have investigated associations of hyperhomocysteinemia with risk of vascular disease among w...

journal_title：Seminars in thrombosis and hemostasis

authors： Verhoef P

更新日期：2000-01-01 00:00:00

abstract：:von Willebrand disease (VWD) was first described nearly a century ago in 1924 by Erik Adolf von Willebrand. Diagnostic testing at the time was very limited and it was not until the mid to late 1900s that more tests became available to assist with the diagnosis and classification of VWD. Two of these tests are based on...

journal_title：Seminars in thrombosis and hemostasis

authors： Just S

更新日期：2017-02-01 00:00:00

abstract：:A prospective randomized double-blind trial was performed comparing conventional low-dose heparin with a LMWH fragment (Kabi 2165, Fragmin) for thromboprophylaxis in elective general abdominal surgical patients. The first dose of the fragment was given in the evening before surgery, and thereafter every evening. There...

journal_title：Seminars in thrombosis and hemostasis

authors： Bergqvist D,Burmark US,Frisell J,Guilbaud O,Hallböök T,Horn A,Lindhagen A,Ljungner H,Ljungström KG,Mätzsch T

更新日期：1990-10-01 00:00:00

abstract：:Point-of-care (POC) testing in hemostasis has experienced a significant increase in the spectrum of available tests and the number of tests performed. Short turn-around time and observation of rapid changes in test results are facilitated. The quality control process in POC testing must encompass a preanalytic (collec...

journal_title：Seminars in thrombosis and hemostasis

authors： Fries D,Streif W

更新日期：2015-02-01 00:00:00

abstract：:The long-term success rate of coronary angioplasty is only 50 to 70% due to restenosis. The pathophysiologic mechanism of this event is mainly mediated by smooth muscle cell proliferation. To some extent, it can be inhibited by heparin. The introduction of LMWHs allows for prophylaxis against restenosis on an outpatie...

journal_title：Seminars in thrombosis and hemostasis

authors： Lojewski B,Bacher P,Iqbal O,Walenga JM,Hoppensteadt DA,Leya F,Fareed J

更新日期：1993-01-01 00:00:00

abstract：:Heparin, a sulfated polysaccharide belonging to the family of glycosaminoglycans, was discovered in the beginning of the 20th century and was initially identified as a procoagulant isolated from liver tissue. After the first application in patients approximately 30 years later, further purification identified the majo...

journal_title：Seminars in thrombosis and hemostasis

authors： Harenberg J,Casu B,Krämer R,Torri G,Naggi A,Krämer S

更新日期：2014-11-01 00:00:00

abstract：:Current guidelines for venous thromboembolism (VTE) primary prophylaxis are based on randomized clinical trials that exclude subjects at a potentially high bleeding risk. Thus no specific recommendation/algorithm for pharmacological prophylaxis in patients with thrombocytopenia and/or platelet dysfunction is available...

journal_title：Seminars in thrombosis and hemostasis

authors： Tufano A,Guida A,Di Minno MN,Prisco D,Cerbone AM,Di Minno G

更新日期：2011-04-01 00:00:00

abstract：:Tissue factor pathway inhibitor (TFPI) is a Kunitz-type serine protease inhibitor found within the vascular system that is known to be released upon heparin administration. Tissue factor pathway inhibitor regulates the extrinsic pathway by inhibiting both factors VIIa and Xa. The role of TFPI in the prevention of thro...

journal_title：Seminars in thrombosis and hemostasis

authors： Jeske W,Hoppensteadt D,Callas D,Koza MJ,Fareed J

更新日期：1996-01-01 00:00:00

abstract：:Although the current therapeutic armamentarium of venous thrombosis encompasses the use of vitamin K antagonists, heparins, and direct oral anticoagulants, these drugs have several important drawbacks. Antisense oligonucleotides are relatively short single-stranded nucleic acid sequences, which hybridize with a target...

journal_title：Seminars in thrombosis and hemostasis

authors： Lippi G,Harenberg J,Mattiuzzi C,Favaloro EJ

更新日期：2015-03-01 00:00:00

abstract：:A new in vitro system for the detection of platelet dysfunction, PFA-100, has been developed. It provides a quantitative measure of platelet function in anticoagulated whole blood. The system comprises a microprocessor-controlled instrument and a disposable test cartridge containing a biologically active membrane. The...

journal_title：Seminars in thrombosis and hemostasis

authors： Kundu SK,Heilmann EJ,Sio R,Garcia C,Davidson RM,Ostgaard RA

更新日期：1995-01-01 00:00:00

abstract：:Severe trauma is the leading cause of death globally. Though improved resuscitation, particularly early initiation, has reduced the 24-hour mortality rate, the overall morbidity and 30-day mortality remain high mostly due to massive hemorrhage and head injury in the early stages and sepsis and multiorgan failure later...

journal_title：Seminars in thrombosis and hemostasis

authors： Kwaan HC

更新日期：2020-03-01 00:00:00

abstract：:Pulmonary embolism (PE) has long been described in children. Nevertheless, most of the algorithms applied to patients within this age range, from diagnosis to therapy, have been adapted from adult protocols. This article reviews the progresses that occurred to PE in children placing them in historical perspective with...

journal_title：Seminars in thrombosis and hemostasis

authors： Brandão LR,Labarque V,Diab Y,Williams S,Manson DE

更新日期：2011-10-01 00:00:00

abstract：:Despite long-standing knowledge about the relationship between thrombosis and atherosclerosis, the specific role of thrombin in modulating atherosclerosis and the response to vascular injury is not well understood. Thrombin receptor stimulation in vitro signals many cellular events that are associated with the respons...

journal_title：Seminars in thrombosis and hemostasis

authors： McNamara CA,Sarembock IJ,Bachhuber BG,Stouffer GA,Ragosta M,Barry W,Gimple LW,Powers ER,Owens GK

更新日期：1996-01-01 00:00:00

abstract：:Eradication of factor VIII (FVIII) specific neutralizing antibodies (also known as inhibitors) by the traditional method of immune tolerance induction (ITI) is costly and unsuccessful in one out of three patients. Furthermore, effective inhibitor prevention strategies are presently lacking. An overview is given in thi...

journal_title：Seminars in thrombosis and hemostasis

authors： Hassan S,Fijnvandraat K,van der Bom JG,Gouw SC

更新日期：2018-09-01 00:00:00

abstract：:The identification of the JAK2 V617F mutation in patients with myeloproliferative disorders (MPDs) represents a major breakthrough in our understanding of the pathogenesis of these diseases. One year after its discovery, an impressive number of publications appeared. These articles confirmed most of the initial result...

journal_title：Seminars in thrombosis and hemostasis

authors： Villeval JL,James C,Pisani DF,Casadevall N,Vainchenker W

更新日期：2006-06-01 00:00:00

abstract：:In this article, three cases, with antithrombin (AT) abnormality "Toyama" (type IIb), AT abnormality "Aomori" (type IIa), and congenital AT deficiency (type I) with pregnancy and delivery managed with administration of both AT concentrates and low-molecular-weight heparin, are described. Additionally, a case of AT-pro...

journal_title：Seminars in thrombosis and hemostasis

authors： Sakuragawa N

更新日期：1997-01-01 00:00:00

abstract：:With the strides being made in the European, Canadian, and American prospective studies of von Willebrand disease (VWD) genotype and phenotype, genetics is increasingly playing a key role in the classification, understanding, and management of VWD. It is anticipated that as gene sequencing becomes easier and more comm...

journal_title：Seminars in thrombosis and hemostasis

authors： Novelli EM,Ragni MV

更新日期：2008-09-01 00:00:00

abstract：:Acute promyelocytic leukemia (APL), once highly fatal, has emerged as the most curable subtype of acute myeloid leukemia in adults. Cure is now expected in approximately 70 to 90% of patients when treatment includes all- TRANS retinoic acid (ATRA) combined with anthracycline-based chemotherapy. Early mortality most of...

journal_title：Seminars in thrombosis and hemostasis

authors： Tallman MS,Abutalib SA,Altman JK

更新日期：2007-06-01 00:00:00

abstract：:Sequencing of the gene encoding for von Willebrand factor (VWF) has brought new insight into the physiology of VWF as well as its pathophysiology in the context of von Willebrand disease (VWD). Molecular testing in VWD patients has shown high variability in the overall genetic background of this condition. Almost 600 ...

journal_title：Seminars in thrombosis and hemostasis

authors： Zolkova J,Sokol J,Simurda T,Vadelova L,Snahnicanova Z,Loderer D,Dobrotova M,Ivankova J,Skornova I,Lasabova Z,Kubisz P,Stasko J

更新日期：2020-06-01 00:00:00

abstract：:Factor (F) VIII is a large gene located near the terminus of the long arm of the X chromosome. It contains 26 exons that code for a signal peptide and a 2332 amino acid polypeptide with three different types of domains, namely A1-A2-B-A3-C1-C2. The A domains are homologous with each other and those of ceruloplasmin; s...

journal_title：Seminars in thrombosis and hemostasis

authors： Thompson AR

更新日期：2003-02-01 00:00:00

abstract：:Current concepts of the cause, pathophysiologic mechanisms, diagnosis, and management of acute and chronic DIC have been discussed. Considerable attention has been devoted to interrelationships that have remained confusing. Only by clearly understanding these pathophysiologic interrelationships can the clinician and l...

journal_title：Seminars in thrombosis and hemostasis

authors： Bick RL

更新日期：1988-10-01 00:00:00

abstract：:Hemophilia A (HA) and hemophilia B (HB) are rare congenital severe bleeding disorders, that may be controlled by proper administration of adequate prophylaxis with factor VIII (FVIII), and factor IX (FIX) concentrates, respectively, to prevent joint damage due to recurrent bleeding. However, approximately 30% of patie...

journal_title：Seminars in thrombosis and hemostasis

authors： Barg AA,Livnat T,Kenet G

更新日期：2018-09-01 00:00:00

abstract：:Mutations in the genes for three complement regulators-complement factor H (CFH), membrane cofactor protein (MCP), and factor I (IF)-have now been described in patients with atypical HUS. The functional effects of these mutations have been studied in detail and have been shown to affect secretion, expression, and regu...

journal_title：Seminars in thrombosis and hemostasis

authors： Kavanagh D,Goodship TH

更新日期：2006-03-01 00:00:00

abstract：:Homocysteine has been identified as an independent risk factor for atherosclerotic and thrombotic disease. Both arterial (cerebrovascular, carotid, coronary, and peripheral arterial) and veno-occlusive disease, jointly termed vascular occlusive disease (VOD) in this review, have been associated with hyperhomocysteinem...

journal_title：Seminars in thrombosis and hemostasis

authors： Guba SC,Fonseca V,Fink LM

更新日期：1999-01-01 00:00:00

abstract：:The extrinsic pathway is probably the predominant pathway in initiating blood coagulation in inflammatory lung diseases. Tissue factor pathway inhibitor (TFPI) is a Kunitz-type protease inhibitor of factor VIIa/tissue factor in the presence of factor Xa. As it has been shown recently that TFPI plasma levels are increa...

journal_title：Seminars in thrombosis and hemostasis

authors： Cella G,Cipriani A,Tommasini A,Rampin E,Sbarai A,Rocconi R,Mazzaro G,Luzzatto G

更新日期：1997-01-01 00:00:00

abstract：:While lupus anticoagulant (LA), anticardiolipin antibodies (aCL), anti-β2 glycoprotein I (anti-β2GPI) antibodies represent the best available and the most widely used tests in the investigation for antiphospholipid syndrome (APS), evidence gathered in recent years indicates that other antiphospholipid antibodies (aPL)...

journal_title：Seminars in thrombosis and hemostasis

authors： Bertolaccini ML,Sanna G

更新日期：2018-07-01 00:00:00

abstract：:Rapid and accurate risk stratification is critical in determining the optimal treatment strategy for patients with acute pulmonary embolism (PE). Early identification of patients with normal blood pressure and a favorable prognosis (low-risk PE) might select a subset of patients for outpatient treatment, which is asso...

journal_title：Seminars in thrombosis and hemostasis

authors： Morillo R,Moores L,Jiménez D

更新日期：2017-07-01 00:00:00

abstract：:Total fibrinolytic activity in the vasculature is finely tuned by the balance between tissue plasminogen activator and plasminogen activator inhibitor type 1 (PAI-1). Although PAI-1 targets plasminogen activators, it also reacts with other serine proteases such as thrombin and factor Xa. The latter was shown to intera...

journal_title：Seminars in thrombosis and hemostasis

authors： Urano T,Ihara H,Suzuki Y,Takada Y,Takada A

更新日期：2000-01-01 00:00:00

abstract：:The functional operation of the cell surface pro-u-PA and plasminogen activating system has previously been shown to depend on the assembly of u-PA receptors, plasminogen binding sites, and their respective ligands at the focal adhesions of cell extensions. We now show that additional factors operate that affect the p...

journal_title：Seminars in thrombosis and hemostasis

authors： Stephens RW,Pöllänen J,Tapiovaara H,Woodrow G,Vaheri A

更新日期：1991-07-01 00:00:00

abstract：:Complications related to hemodialysis vascular access continue to have a major impact on morbidity and mortality. Vascular access dysfunction is the single most important factor that determines the quality of dialysis treatment. Vascular access stenosis is a common complication that develops in a great majority of pat...

journal_title：Seminars in thrombosis and hemostasis

authors： Masud A,Costanzo EJ,Zuckerman R,Asif A

更新日期：2018-02-01 00:00:00